Strs Ohio Acquires 1,600 Shares of AMAG Pharmaceuticals, Inc. (AMAG)

Strs Ohio boosted its holdings in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 4.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,500 shares of the specialty pharmaceutical company’s stock after buying an additional 1,600 shares during the period. Strs Ohio’s holdings in AMAG Pharmaceuticals were worth $600,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. HighPoint Advisor Group LLC acquired a new stake in shares of AMAG Pharmaceuticals in the 3rd quarter valued at $188,000. Tower Research Capital LLC TRC acquired a new stake in shares of AMAG Pharmaceuticals in the 3rd quarter valued at $173,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of AMAG Pharmaceuticals in the 3rd quarter valued at $279,000. Virtu Financial LLC acquired a new stake in shares of AMAG Pharmaceuticals in the 4th quarter valued at $217,000. Finally, Martingale Asset Management L P acquired a new stake in shares of AMAG Pharmaceuticals in the 3rd quarter valued at $309,000.

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of AMAG Pharmaceuticals in a research note on Friday, November 23rd. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 17th. B. Riley set a $21.00 target price on shares of AMAG Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 16th. JPMorgan Chase & Co. downgraded shares of AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and reduced their target price for the company from $20.00 to $18.00 in a research note on Tuesday, November 6th. Finally, Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $20.97.

Shares of NASDAQ:AMAG opened at $15.19 on Friday. AMAG Pharmaceuticals, Inc. has a 52 week low of $11.95 and a 52 week high of $26.10. The company has a current ratio of 3.17, a quick ratio of 2.72 and a debt-to-equity ratio of 0.35.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, February 7th. The specialty pharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.98) by $0.38. The business had revenue of $88.10 million for the quarter, compared to the consensus estimate of $95.21 million. AMAG Pharmaceuticals had a negative net margin of 13.07% and a negative return on equity of 17.10%. The firm’s quarterly revenue was down 31.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. As a group, sell-side analysts predict that AMAG Pharmaceuticals, Inc. will post -3.28 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.themarketsdaily.com/2019/02/09/strs-ohio-acquires-1600-shares-of-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Read More: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply